Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences.
| Conference Details | |
| Wells Fargo 21st Annual Healthcare Conference | |
| Format: | Fireside chat and 1x1s |
| Presentation Date: | September 8, 2026 |
| Time: | 1:30 pm ET |
| Location: | Boston, MA |
| Webcast link: | HERE |
| Cantor Global Healthcare Conference, New York | |
| Format: |
1x1s |
| Participation Date: |
September 10, 2026 |
| Location: |
New York, NY |
| H.C. Wainwright 28th Annual Global Investment Conference |
|
| Format: |
Fireside chat and 1x1s |
| Presentation Date: |
September 15, 2026 |
| Time: |
10:30 am ET |
| Location: |
New York, NY |
| Webcast link: |
HERE |
To request a 1x1 meeting, please contact your representative at the relevant bank.
Webcasts of the presentations will be available for approximately 90 days following each event on the “News & Events” section of Milestone's website www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
